Sponsored Content by The Janssen Pharmaceutical Companies of Johnson & Johnson | Authors


Precise Management of EGFR exon 20-Positive Non–Small Cell Lung Cancer

July 26, 2021

Research shows that methods used to treat the wide epidermal growth factor receptor-positive population are often not successful for patients with specific biomarkers like EGFR exon 20 insertion mutations, highlighting an ongoing need for more targeted therapies.